Dry Skin
Conditions
Brief summary
This double-blinded, randomized, placebo-controlled study aimed to evaluate the efficacy and safety of AP collagen peptides (APCP) containing 3% Glycine-Proline-Hydroxyproline (GPH) on improving skin health. Subjects with dried skin were randomly assigned to receive placebo or APCP once daily for 12 weeks.
Interventions
DIETARY_SUPPLEMENTAP collagen peptide
Health functional food
DIETARY_SUPPLEMENTPlacebo
placebo
Sponsors
Amorepacific Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
35 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Those whose eye wrinkles are Grade 3 or higher in the visual evaluation * Those whose moisture retention in both cheeks measured by Corneometer® is 49 A.U. or less * A person who has agreed to participate in this human application test before the start of the human application test and filled out the Informed Consent Form
Exclusion criteria
* Those with skin diseases such as atopic dermatitis and psoriasis * Those who are sensitive to or allergic to the food ingredients for this trial foods * Those with skin abnormalities such as spots, acne, erythema, and hypersensitive skin at the test site * People who take diet pills (absorbent and antidepressants, appetite suppressants, etc.) and contraceptives or hormones or diuretics within one month based on visit1 * Those who have used functional cosmetics for wrinkle improvement, highly moisturizing cosmetics, or skincare devices within 2 weeks of visit 1 * A person who used steroid-containing outer skin for more than one month to treat skin diseases * A person who has received chemical and physical treatment (pattern, epidermis, lasers, procedures, etc.) in the test area within six months prior to the start of the test * Visit 1 A person who has participated in other interventional clinical tests (including human application tests) within one month of the standard or plans to participate in other interventional clinical tests (including human application tests) after the start of this human application test * A person who judges that the tester is inappropriate for this test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in epidermal hydration | Baseline, 12 week | skin hydration measured by MoistureMeter-D compact |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in skin gloss | Baseline, 12 week | skin roughness measured by Skinglossmeter |
| Change from baseline in stratum corneum condition | Baseline, 12 week | stripped using 10 tape strips (D-Squame) and measured by VisioScan |
| Change from baseline in skin roughness (texture) | Baseline, 12 week | skin roughness measured by PRIMOS |
| Change of Natural moisturizing factor in stratum corneum | Baseline, 12 week | Ultra-performance liquid chromatography system etc. |
| Change from baseline in TEWL | Baseline, 12 week | Transepidermal water loss measured by vapometer |
| Change of Ceramides in stratum corneum | Baseline, 12 week | ultra-performance liquid chromatography system etc. |
Countries
South Korea
Outcome results
None listed